HC Wainwright Reiterates “Buy” Rating for Cocrystal Pharma (NASDAQ:COCP)

HC Wainwright restated their buy rating on shares of Cocrystal Pharma (NASDAQ:COCP) in a research note published on Wednesday morning,Benzinga reports. They currently have a $7.00 price objective on the stock.

Cocrystal Pharma Stock Performance

COCP stock opened at $2.00 on Wednesday. The firm has a fifty day moving average price of $2.16 and a 200 day moving average price of $1.99. Cocrystal Pharma has a fifty-two week low of $1.33 and a fifty-two week high of $3.26. The firm has a market cap of $20.35 million, a PE ratio of -1.08 and a beta of 1.53.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.